Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

A gender factor in shaping T-cell immunity to melanoma.

Dronca RS, Dong H.

Front Oncol. 2015 Feb 2;5:8. doi: 10.3389/fonc.2015.00008. eCollection 2015. No abstract available.

2.

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma.

Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS.

Melanoma Res. 2015 Feb;25(1):59-63. doi: 10.1097/CMR.0000000000000125.

PMID:
25396683
3.

Immunomodulatory antibody therapy of cancer: the closer, the better.

Dronca RS, Dong H.

Clin Cancer Res. 2015 Mar 1;21(5):944-6. doi: 10.1158/1078-0432.CCR-14-2111. Epub 2014 Oct 28.

PMID:
25351746
4.

Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I.

Moser JC, Dronca RS, Markovic SN, Mansfield AS.

Mayo Clin Proc. 2014 Aug;89(8):1164-5. doi: 10.1016/j.mayocp.2014.06.001. No abstract available.

PMID:
25092366
5.

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN.

Mayo Clin Proc. 2014 Apr;89(4):520-35. doi: 10.1016/j.mayocp.2014.01.006. Review.

6.

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Shah DJ, Dronca RS.

Mayo Clin Proc. 2014 Apr;89(4):504-19. doi: 10.1016/j.mayocp.2014.02.002. Review.

7.

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR.

J Thorac Oncol. 2013 Oct;8(10):1335-8. doi: 10.1097/JTO.0b013e3182a00f41.

PMID:
24457244
8.

Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota.

Lowe GC, Saavedra A, Reed KB, Velazquez AI, Dronca RS, Markovic SN, Lohse CM, Brewer JD.

Mayo Clin Proc. 2014 Jan;89(1):52-9. doi: 10.1016/j.mayocp.2013.09.014.

9.

Rare presentations of primary melanoma and special populations: a systematic review.

Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN.

Am J Clin Oncol. 2014 Dec;37(6):635-41. doi: 10.1097/COC.0b013e3182868e82. Review.

PMID:
23563206
10.

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.

Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC.

BJU Int. 2013 Jun;111(7):1046-53. doi: 10.1111/bju.12075. Epub 2013 Apr 2.

PMID:
23551810
11.

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN.

Am J Clin Oncol. 2014 Aug;37(4):369-76. doi: 10.1097/COC.0b013e31827b45d4.

12.

Personalized therapy for metastatic melanoma: could timing be everything?

Dronca RS, Leontovich AA, Nevala WK, Markovic SN.

Future Oncol. 2012 Nov;8(11):1401-6. doi: 10.2217/fon.12.126. Review.

13.

Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN.

Clin Exp Immunol. 2012 Nov;170(2):186-93. doi: 10.1111/j.1365-2249.2012.04644.x.

14.

Melanoma brain metastases and vemurafenib: need for further investigation.

Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN.

Mayo Clin Proc. 2012 Oct;87(10):976-81. doi: 10.1016/j.mayocp.2012.07.006.

15.

Fluctuation of systemic immunity in melanoma and implications for timing of therapy.

Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jan 1;4:958-75.

PMID:
22201928
16.

The dynamic human immune response to cancer: it might just be rocket science.

Holtan SG, Dronca RS, Nevala WK, Porrata LF, Mansfield AS, Block MS, Leontovich AA, Grotz TE, Turner JD, Frisch HP, Markovic SN.

Immunotherapy. 2011 Sep;3(9):1021-4. doi: 10.2217/imt.11.109. No abstract available.

17.

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S35-41. doi: 10.1002/cyto.b.20546.

18.

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma.

Jevremovic D, Dronca RS, Morice WG, McPhail ED, Kurtin PJ, Zent CS, Hanson CA.

Leuk Res. 2010 Sep;34(9):1235-8. doi: 10.1016/j.leukres.2010.03.020. Epub 2010 Apr 1.

PMID:
20362334
19.

VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.

Dronca RS, Steensma DP.

Nat Clin Pract Oncol. 2008 Sep;5(9):504-5. doi: 10.1038/ncponc1202. Epub 2008 Jul 22.

PMID:
18648351
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk